Your browser doesn't support javascript.
loading
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.
Lee, G A; Aktaa, S; Baker, E; Gale, C P; Yaseen, Israa F; Gulati, G; Asteggiano, R; Szmit, S; Cohen-Solal, A; Abdin, A; Jurczak, W; Garrido Lopez, P; Sverdlov, A L; Tocchetti, C G; Barac, A; Parrini, I; Zamorano, P; Iakobishvili, Z; Pudil, R; Badimon, L; Kirby, A M; Blaes, A H; Farmakis, D; Curigliano, G; Stephens, R; Lyon, A R; Lopez-Fernandez, T.
  • Lee GA; Division of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK.
  • Aktaa S; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Baker E; Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
  • Gale CP; Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Yaseen IF; Division of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK.
  • Gulati G; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Asteggiano R; Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
  • Szmit S; Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Cohen-Solal A; Baghdad Heart Center, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq.
  • Abdin A; Scientific Council of Cardiology, Iraqi Board for Medical Specializations, Baghdad, Iraq.
  • Jurczak W; Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway.
  • Garrido Lopez P; Department of Cardiology, Division of Medicine, Oslo University Hospital, Ullevål, Oslo, Norway.
  • Sverdlov AL; School of Medicine, Insubria University, Varese, Italy.
  • Tocchetti CG; LARC (Laboratorio Analisi e Ricerca Clinica), C.so Venezia 10, Turin, Italy.
  • Barac A; Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, Otwock, Poland.
  • Parrini I; Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Zamorano P; Research Medical Unit INSERM U-942, University of Paris, Paris, France.
  • Iakobishvili Z; Cardiology Department, Hôpitaux de Paris, Hôpital Lariboisière 2 Rue Ambroise Paré, Paris, France.
  • Pudil R; Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany.
  • Badimon L; MSC National Research Institute of Oncology, Garnarska 11, 31-115 Krakow, Poland.
  • Kirby AM; Jefe Servicio Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Blaes AH; Newcastle Centre of Excellence in Cardio-Oncology, Calvary Mater Newcastle, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, NSW, Australia.
  • Farmakis D; Cardio-Oncology Unit, Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples,
  • Curigliano G; Cardio-oncology Program, MedStar Heart and Vascular Institute, Washington DC, USA.
  • Stephens R; Department of Cardiology, Mauriziano Hospital, Turin, Italy.
  • Lyon AR; University Hospital Ramon y Cajal, Madrid, Spain.
  • Lopez-Fernandez T; Department of Community Cardiology, Clalit Health Services, Tel Aviv Jaffa, Israel.
Eur Heart J Qual Care Clin Outcomes ; 9(1): 1-7, 2022 12 13.
Article en En | MEDLINE | ID: mdl-36316010
ABSTRACT

AIMS:

To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND

RESULTS:

We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.

CONCLUSION:

We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiología / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiología / Neoplasias Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article